We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
- Authors
Sharath S. Hegde; Stacey Difuntorum; Robert Skinner; Justin Trumbull; Kevin M. Krause
- Abstract
Objectives The aim of the study was to compare the efficacies of telavancin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous vancomycin-intermediate S. aureus (hVISA) in a neutropenic murine bacteraemia model. Methods Immunocompromised mice (female non-Swiss albino, 18–30 g) were inoculated intraperitoneally with 107 cfu/mL of GISA (strain HIP-5836 or Mu50) or hVISA (strain Mu3). Infected mice received a subcutaneous dose of telavancin (40 mg/kg) or vancomycin (110 mg/kg) at 4 and 16 h post-inoculation. Control animals received a subcutaneous dose of vehicle at 4 h post-inoculation only. Blood and spleen bacterial titres were quantified in drug-treated mice at 16, 28 and 52 h post-inoculation. Results Telavancin was 8-fold more potent than vancomycin against HIP-5836 (MIC 1 versus 8 mg/L), 16-fold more potent against Mu50 (MIC 0.5 versus 8 mg/L) and 8-fold more potent against Mu3 (MIC 0.25 versus 2 mg/L). Telavancin produced significant (P P Conclusions Telavancin was more efficacious than vancomycin in clearing infections caused by GISA strains HIP-5836 and Mu50 and hVISA strain Mu3 in a neutropenic mouse bacteraemia model. Further evaluation of telavancin for GISA and hVISA bacteraemia is warranted.
- Subjects
CLINICAL drug trials; COMPARATIVE medicine; ANTIBIOTICS; VANCOMYCIN; STAPHYLOCOCCUS aureus infections; SPLEEN; GLYCOPEPTIDES; BACTEREMIA; LABORATORY mice; THERAPEUTICS
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2009, Vol 63, Issue 4, p763
- ISSN
0305-7453
- Publication type
Article
- DOI
10.1093/jac/dkp001